CANbridge Pharmaceuticals, Inc. announced positive preliminary results from the ongoing Phase 1b study of omoprubart, a novel, long-acting, anti-C5 complement recombinant humanized monoclonal antibody, in paroxysmal nocturnal hemoglobinuria in China.
